Emerging Trends in Immunotherapy for Cancer
Round 1
Reviewer 1 Report
An excellent review covering immunotherapeutics and their uses, expertly written and well described.
A few minor points and suggested changes.
Section 3.1. Adaptive immune checkpoints - Please include the full names for PD1 and PD-L1. Also please include descriptions of other immune checkpoints including OX40, VISTA etc.
Section 3.4. Limitations and challenges of ICI therapy - Please include a comment on the durability of response to each therapy
Section 4.1. Limitations and challenges of CAR T therapy - Please include the full name for B cell maturation antigen
Section 7. Oncolytic viruses - Please include a short description of the mechanism of action for Delytact as per the previous examples
Author Response
Reviewer-1
We thank Reviewer-1 for reviewing this manuscript and appreciating our work. As suggested, we have now incorporated all the changes indicated by Reviewer-1 in the revised version of the manuscript.
Comments and Suggestions for Authors:
#1 An excellent review covering immunotherapeutics and their uses, expertly written and well described.
Authors' response: Thank you for appreciating our manuscript.
A few minor points and suggested changes.
#2. Section 3.1. Adaptive immune checkpoints - Please include the full names for PD1 and PD-L1. Also please include descriptions of other immune checkpoints including OX40, VISTA etc.
Authors' response: We have included full names for PD-1 and PDL-1, and incorporated descriptions of OX40 and VISTA (sections 3.1.7 and 3.1.8). Thanks for the suggestion.
#3. Section 3.4. Limitations and challenges of ICI therapy - Please include a comment on the durability of response to each therapy
Authors' response: As suggested we have now included a brief description of the durability of response to ICI therapies (section 3.4).
Section 4.1. Limitations and challenges of CAR T therapy - Please include the full name for B cell maturation antigen
Authors' response: Included as indicated (section 4.5)
Section 7. Oncolytic viruses - Please include a short description of the mechanism of action for Delytact as per the previous examples
Authors' response: As suggested we have now included a brief description of the mechanism of action for Delytact (Section 7).
Reviewer 2 Report
Over the past 10 years, the importance of immunology in understanding cancer has multiplied. 100 years ago, immunology and cancer were brought together by Paul Ehrlich.
Today, physicians have a plethora of therapeutic options and were overwhelmed by the present possibilities.
This review presents all aspects of immunotherapy for cancer and thus provides a valuable overview of the existing possibilities. It is comprehensive and, in my opinion, has no gaps. The figures and tables facilitate the understanding of the dense text.
I would like to raise two minor points related to the structure:
(1) Why line 444 “CAR T cells and line 507 “CAR NK cells are not numbered?
(1) The structure with many sub-points makes the reading of this 38-page review difficult. A table of contents on the first page would be helpful (decision of the journal).
Author Response
Reviewer-2
We thank Reviewer-2 for reviewing this manuscript and appreciating our work. As suggested, we have now incorporated all the changes indicated by Reviewer-1 in the revised version of the manuscript.
Comments and Suggestions for Authors
#1. Over the past 10 years, the importance of immunology in understanding cancer has multiplied. 100 years ago, immunology and cancer were brought together by Paul Ehrlich. Today, physicians have a plethora of therapeutic options and were overwhelmed by the present possibilities. This review presents all aspects of immunotherapy for cancer and thus provides a valuable overview of the existing possibilities. It is comprehensive and, in my opinion, has no gaps. The figures and tables facilitate the understanding of the dense text.
Authors' response: Thank you for your kind appraisal.
I would like to raise two minor points related to the structure:
- Why line 444 “CAR T cells and line 507 “CAR NK cells are not numbered?
Authors' response: We have included the numbering in the revised version.
- The structure with many sub-points makes the reading of this 38-page review difficult. A table of contents on the first page would be helpful (decision of the journal).
Authors' response: Thanks for the thoughtful suggestion. We will discuss with the journal if they have a provision of including a table of contents.
Reviewer 3 Report
Evaluation
Manuscript ID: diseases-1882685
Type of manuscript: Review
Title: Emerging Trends in Immunotherapy for Cancer
The authors describe a good review on cancer immunotherapy.
Congratulations for the effort and work.
However, I have one comment for the authors.
1.- line 437: “Three types of adoptive cell therapies have been developed such as CART (chimeric antigen receptor T cells), 438 TCRs (engineered T-cell receptors), and TILs (tumor-infiltrating lymphocytes)”.
CART therapy is mentioned extensively, however, the other two types of adoptive therapy are not described. Although CAR-T is a leader in adoptive immunotherapy, the other two types should be briefly described.
Author Response
Reviewer-3
We thank Reviewer-3 for reviewing this manuscript and appreciating our work. As suggested, we have now incorporated all the changes indicated by Reviewer-3 in the revised version of the manuscript.
Comments and Suggestions for Authors
#The authors describe a good review on cancer immunotherapy. Congratulations for the effort and work.
Authors' response: Thank you for your kind appraisal.
However, I have one comment for the authors.
1.- line 437: “Three types of adoptive cell therapies have been developed such as CART (chimeric antigen receptor T cells), 438 TCRs (engineered T-cell receptors), and TILs (tumor-infiltrating lymphocytes)”. CART therapy is mentioned extensively, however, the other two types of adoptive therapy are not described. Although CAR-T is a leader in adoptive immunotherapy, the other two types should be briefly described.
Authors' response: We appreciate your thoughtful advice. In the revised version we have now included a short description of TILs and TCR therapy (sections 4.1 and 4.2)
